
|Videos|March 28, 2023
Managing Disease Progression in Patients with EGFR-mutated mNSCLC
Continuing the discussion of the presented case of EGFR exon 20-mutant mNSCLC, Dr Velázquez Mañana outlines how the patient experienced disease progression on first-line treatment, after which the panel shares clinical insights and best practices on how they might approach subsequent treatment selection in this scenario.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5



















